Cat# : THP-0027
|THP-0027||Botulinum Toxin Type A||April 02, 2023||100U||$398||
|Add to Cart Online Order Request a Bulk Order|
|Product Name:||Botulinum Toxin Type A|
|Description:||Purified botulinum toxin A from Clostridium botulinum, purified from culture via dialysis and acid precipitation.|
|Molecular Weight:||900000.0 Da|
|Purity:||>99% by SDS-Page and HPLC analysis|
|Endotoxin Level:||<0.01 EU per 1 μg of the peptide by the LAL method|
|Drug Name:||Botulinum Toxin Type A|
|Applications:||For the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. Also used cosmetically to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) as well as for the treatment of excessive underarm sweating.|
|Examples of Clinical Use:||Cervical dystonia, severe primary axillary hyperhidrosis, strabismus and blepharospasm|
|Pharmacodynamics:||A 150 kDa neurotoxic protein produced from fermentation of Hall strain Clostridium botulinum type A grown in a medium containing casein hydrolysate, glucose and yeast extract. It is purified from the culture solution by dialysis and a series of acid precipitations to a complex consisting of the neurotoxin, and several accessory proteins. The product is not expected to be present in the peripheral blood at measurable levels following IM or intradermal injection at the recommended doses. The recommended quantities of neurotoxin administered at each treatment session are not expected to result in systemic, overt distant clinical effects, i.e. muscle weakness, in patients without other neuromuscular dysfunction. However, sub-clinical systemic effects have been shown by single-fiber electromyography after IM doses of botulinum toxins appropriate to produce clinically observable local muscle weakness.|
|Mechanism of action:||Botulinum Toxin Type A blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings.|
|Affected organisms:||Humans and other mammals|
|Targets:||Target 1. Synaptosomal-associated protein 25; Target 2. Rho-related GTP-binding protein RhoB|
For more information on how our products could help advance your project, please contact us.
ENTER YOUR EMAIL HERE TO SUBSCRIBE.
Copyright © Creative BioMart. All Rights Reserved.